WO2003068268A3 - Treatment, diagnosis and imaging of disease - Google Patents

Treatment, diagnosis and imaging of disease Download PDF

Info

Publication number
WO2003068268A3
WO2003068268A3 PCT/EP2003/001461 EP0301461W WO03068268A3 WO 2003068268 A3 WO2003068268 A3 WO 2003068268A3 EP 0301461 W EP0301461 W EP 0301461W WO 03068268 A3 WO03068268 A3 WO 03068268A3
Authority
WO
WIPO (PCT)
Prior art keywords
mcl
cells
moiety
imaging
methods
Prior art date
Application number
PCT/EP2003/001461
Other languages
French (fr)
Other versions
WO2003068268A2 (en
Inventor
Sara Ek
Carl Arne Krister Borrebaeck
Mats Ehinger
Original Assignee
Bioinvent Int Ab
Sara Ek
Carl Arne Krister Borrebaeck
Mats Ehinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203480A external-priority patent/GB0203480D0/en
Priority claimed from GB0215095A external-priority patent/GB0215095D0/en
Application filed by Bioinvent Int Ab, Sara Ek, Carl Arne Krister Borrebaeck, Mats Ehinger filed Critical Bioinvent Int Ab
Priority to AU2003210266A priority Critical patent/AU2003210266A1/en
Publication of WO2003068268A2 publication Critical patent/WO2003068268A2/en
Publication of WO2003068268A3 publication Critical patent/WO2003068268A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.
PCT/EP2003/001461 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease WO2003068268A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003210266A AU2003210266A1 (en) 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0203480.9 2002-02-14
GB0203480A GB0203480D0 (en) 2002-02-14 2002-02-14 Treatment diagnosis and imaging of disease
GB0215095.1 2002-06-29
GB0215095A GB0215095D0 (en) 2002-06-29 2002-06-29 Treatment, diagnosis and imaging of imaging of disease

Publications (2)

Publication Number Publication Date
WO2003068268A2 WO2003068268A2 (en) 2003-08-21
WO2003068268A3 true WO2003068268A3 (en) 2004-03-11

Family

ID=27736212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001461 WO2003068268A2 (en) 2002-02-14 2003-02-13 Treatment, diagnosis and imaging of disease

Country Status (2)

Country Link
AU (1) AU2003210266A1 (en)
WO (1) WO2003068268A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1679372B1 (en) * 2003-10-30 2009-02-18 Kazusa DNA Research Institute Foundation Novel plexin polypeptide, dna encoding the same and use thereof
GB2435882A (en) * 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
KR101958753B1 (en) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human cd27 and uses thereof
EA030828B1 (en) 2012-03-15 2018-10-31 Янссен Байотек, Инк. Human anti-cd27 antibodies, methods and uses
KR20210011919A (en) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. Anti-CD27 antibody and anti-PD-L1 antibody and bispecific construct

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
WO2001097858A2 (en) * 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2002004021A1 (en) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010460A1 (en) * 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody
WO2001097858A2 (en) * 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2002004021A1 (en) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EK S. ET AL: "Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.", CANCER RESEARCH, (1 AUG 2002) 62/15 (4398-4405). REFS: 62 ISSN: 0008-5472 CODEN: CNREA8, 1 August 2002 (2002-08-01), XP002254996 *
ROBETORYE R S ET AL: "Microarray analysis of B-cell lymphoma cell lines with the t(14;18)", JOURNAL OF MOLECULAR DIAGNOSTICS 2002 UNITED STATES, vol. 4, no. 3, 2002, pages 123 - 136, XP002254997, ISSN: 1525-1578 *

Also Published As

Publication number Publication date
AU2003210266A1 (en) 2003-09-04
AU2003210266A8 (en) 2003-09-04
WO2003068268A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
Streckfus et al. The use of surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study
RU2485974C2 (en) Identifying tumour antigens for diagnosing and therapy
Bangur et al. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis
WO2007056680A3 (en) Methods and arrays for identifying human microflora
EP2293074A3 (en) Method for diagnosing neuro-degenerative disease
KR20120065959A (en) Markers for predicting gastric cancer prognostication and method for predicting gastric cancer prognostication using the same
JP2009540803A5 (en)
Yeh et al. H. pylori cagL amino acid sequence polymorphism Y58E59 induces a corpus shift of gastric integrin α5β1 related with gastric carcinogenesis
MXPA06012232A (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies.
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
KR20210049117A (en) Bronchial Precancerous Lesion Severity and Methods Related to Progression
Li et al. Abnormal DNA-PKcs and Ku 70/80 expression may promote malignant pathological processes in gastric carcinoma
CN106662543A (en) Non-invasive gene mutation detection in lung cancer patients
CN105190313B (en) With the relevant marker of WNT inhibitor
JP2011517937A (en) In vitro diagnostic method for diagnosis of somatic and ovarian cancer
WO2004063712A3 (en) Methods for diagnosis and prognosis of cancer
CN107208159A (en) Host DNA as Crohn's disease biomarker
ATE419533T1 (en) METHOD/PREPARATION FOR DETECTING PANCREATIC CANCER
DE60306517D1 (en) METHOD FOR DETECTING AND QUANTIFYING TUMOR CELLS DERIVED FROM TOMORROWING TUMOR CELLS
RU2008123385A (en) METHODS FOR DIAGNOSTIC OF LIVER DISEASES AND SCREENING OF MOLECULES FOR THE TREATMENT OF THESE DISEASES
EP1159614A4 (en) Diagnostic methods for asthma
WO2007101676A3 (en) Treatment, diagnosis and imaging of mantle cell lymphoma
US20110151469A1 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
Del Sordo et al. HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP